Wagner Marek, Nishikawa Hiroyoshi, Koyasu Shigeo
Innate Immunity Research Group, Life Sciences and Biotechnology Center, Łukasiewicz Research Network-PORT Polish Center for Technology Development, Wrocław, Poland.
Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Nature. 2025 Jan;637(8045):296-303. doi: 10.1038/s41586-024-08194-2. Epub 2025 Jan 8.
Our understanding of type 2 immunity has undergone a substantial transformation in recent years, revealing previously unknown functions. Beyond its canonical role in defence against parasitic helminth infections, type 2 immunity safeguards the host through additional mechanisms, including the suppression of excessive type 1 immune responses, regulation of tissue repair and maintenance of adipose tissue homeostasis. However, unlike type 1 immune responses, type 2 immunity is perceived as a potential promoter of tumorigenesis. Emerging evidence challenges this perspective, painting a more nuanced picture in which type 2 immunity might protect against or even actively suppress tumour growth and progression. In this Review, we explore discoveries that highlight the potential of type 2 immunity in reshaping the landscape of cancer immunotherapies.
近年来,我们对2型免疫的理解发生了重大转变,揭示了以前未知的功能。除了在抵御寄生性蠕虫感染中发挥的经典作用外,2型免疫还通过其他机制保护宿主,包括抑制过度的1型免疫反应、调节组织修复和维持脂肪组织稳态。然而,与1型免疫反应不同,2型免疫被认为是肿瘤发生的潜在促进因素。新出现的证据对这一观点提出了挑战,描绘了一幅更为细致入微的图景,即2型免疫可能预防甚至积极抑制肿瘤生长和进展。在本综述中,我们探讨了一些发现,这些发现凸显了2型免疫在重塑癌症免疫治疗格局方面的潜力。